Patrick Lamy - 10 Jun 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Reporting relationship: Senior VP, Commercial Strategy
Issuer ticker: AKRO
Reported as of: 10 Jun 2025
Net transaction value: -$49,625
SEC form: 4
Accepted by SEC: 12 Jun 2025, 18:32:59 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Young, Attorney-in-Fact

Key filing fact

Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 12 Jun 2025.

Key facts

This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2025, 18:32.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: -$49,625.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001961273 Primary reporting owner

Lamy Patrick

Relationship: Senior VP, Commercial Strategy
Address: C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO
Signature: /s/ Jonathan Young, Attorney-in-Fact
Signature date: 12 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKRO transaction

Common Stock

Sale

Transaction value: $49,625
Shares: -919
Change %: -2.7%
Price: $54.00
Shares after: 32,573
Date: 10 Jun 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.93 to $54.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.